Close Menu

NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that it has entered a collaboration with Five Prime Therapeutics to develop a blood-based companion diagnostic assay for use with Five Prime's investigational drug candidate, bemarituzumab.

Under the agreement, PGDx is creating and validating a circulating tumor DNA test to identify the approximately 10 percent of gastric and gastroesophageal junction cancer patients whose tumors are FGFR2 gene-amplified and therefore eligible for treatment with the drug.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.